scholarly journals Interleukin 6, osteoprotegerin, sRANKL and bone metabolism in inflammatory bowel diseases

2018 ◽  
Vol 27 (4) ◽  
pp. 449-453 ◽  
Author(s):  
Iwona Krela-Kaźmierczak ◽  
Aleksandra Szymczak-Tomczak ◽  
Liliana Łykowska-Szuber ◽  
Ewa Wysocka ◽  
Michał Michalak ◽  
...  
Keyword(s):  
Bone Metabolism ◽  
Inflammatory Bowel Diseases ◽  
Interleukin 6 ◽  
Bowel Diseases ◽  
Inflammatory Bowel

scholarly journals DIAGNOSTIC VALUE OF INTERLEUKIN-6 AND D-DIMER IN INFLAMMATORY BOWEL DISEASES

2021 ◽  
pp. 92-96
Author(s):  
А. P. Lutsyk ◽  
D. V. Shorikova
Keyword(s):  
Inflammatory Bowel Diseases ◽  
Interleukin 6 ◽  
Roc Analysis ◽  
Diagnostic Value ◽  
Control Group ◽  
Active Process ◽  
Montreal Classification ◽  
Bowel Diseases ◽  
Inflammatory Bowel ◽  
D Dimer

The article deals with the diagnostic value of changes in the content of interleukin-6 and D-dimer in patients with inflammatory bowel diseases (IBD) - Ulcerative Colitis (UC) and Crohn Disease (CD). Materials and methods: We have studied 34 patients with UC and 18 people with CD with continuously recurrent course. There are also analysed data of 15 patients with UC and 15 patients with CD in period of the remission. The control group included 30 healthy volunteers. Clinical, endoscopic examination, an immunoassay determination of the content of interleukin-6 (IL-6) and D-dimer, was carried out. CD activity was assessed using the Chron’s disease activity index. The localization of CD was established according to the Montreal classification. The clinical activity of the disease in patients with UC was determined using the classification according to Truelove-Witts. The value of the index consisted of the sum of points for each indicator, which allowed determining the activity of the inflammatory process. Statistical processing was performed using STATISTICA 10.0 (StatSoft. Inc., USA), at p<0.05, the discrepancies between the obtained data were considered statistically significant. Research results. According to the obtained data, mild activity was found in 7 patients with UC (20.6%) and 4 - with CD (22.3%), moderate severity - in 17 (50.0%) and 8 (44.4%) patients, severe - in 10 (29.4%) and 6 (33.3%) patients. In the remission stage, 15 patients with UC and 15 patients with CD were examined. According to the Montreal classification, lesions of the upper gastrointestinal tract (L4) were observed in 4 patients with CD (22.2%), terminal ileitis (L1) occurred in 10 patients (55.6%), 4 patients were diagnosed with ileocolitis (L3) - 22.2%. It has been established that patients with an active course of UC and CD had a higher level of proinflammatory markers and thrombosis markers (D-dimer and IL-6) compared with inactive course and control group (p<0.05). The D-dimer content in UC was 690±315 pg/l. It is confirmed the increase of the content of this marker in 2.55 times compared to control group and in 1.43 times than inactive course of the disease respectively. The level of IL-6 at active in course of UC was 3.36±1.78 pg/ml, increasing in 2.07 times against control and in 1.72 times compared with group of remission. In the active course of CD, the level of D-dimer reached 720±267 pg/ml, increasing in 2.67 times in relation to control and in 1.60 times with respect to patients under remission. The content of IL-6 in the active course of CD reached 4.07±2.17 pg/ml, increasing in 2.85 times in comparison to healthy individuals and in 2.83 times relatively patients with remission. While using the ROC-analysis, the most sensitive value as a “cut point” for the diagnosis of the active process in the course of IBD can be considered the content of the D-dimer in an amount of more than 650 pg/l. The calculated AUC in ROC-analysis for the IL-6 content was 73.7%±6.14% (61.7 - 85.7, p<0.001), indicating the prognostic value of the model. The values of the IL-6 content of more than 2.80 pg/ml are diagnostically significant to predict the active process in IBD.

scholarly journals Interleukin 6: biological significance and role in inflammatory bowel diseases

2021 ◽  
Vol 30 (4) ◽  
pp. 465-469
Author(s):  
Agnieszka Pawłowska - Kamieniak ◽  
Paulina Krawiec ◽  
Elżbieta Pac-Kożuchowska
Keyword(s):  
Inflammatory Bowel Diseases ◽  
Interleukin 6 ◽  
Biological Significance ◽  
Bowel Diseases ◽  
Inflammatory Bowel

scholarly journals Advances in the understanding of mineral and bone metabolism in inflammatory bowel diseases

2011 ◽  
Vol 300 (2) ◽  
pp. G191-G201 ◽  
Author(s):  
Fayez K. Ghishan ◽  
Pawel R. Kiela
Keyword(s):  
Vitamin D ◽  
Bone Metabolism ◽  
Inflammatory Mediators ◽  
Inflammatory Bowel Diseases ◽  
Experimental Models ◽  
Mineral Density ◽  
Anabolic Hormone ◽  
Increased Risk ◽  
Bowel Diseases ◽  
Inflammatory Bowel

Chronic inflammatory disorders such as inflammatory bowel diseases (IBDs) affect bone metabolism and are frequently associated with the presence of osteopenia, osteoporosis, and increased risk of fractures. Although several mechanisms may contribute to skeletal abnormalities in IBD patients, inflammation and inflammatory mediators such as TNF, IL-1β, and IL-6 may be the most critical. It is not clear whether the changes in bone metabolism leading to decreased mineral density are the result of decreased bone formation, increased bone resorption, or both, with varying results reported in experimental models of IBD and in pediatric and adult IBD patients. New data, including our own, challenge the conventional views, and contributes to the unraveling of an increasingly complex network of interactions leading to the inflammation-associated bone loss. Since nutritional interventions (dietary calcium and vitamin D supplementation) are of limited efficacy in IBD patients, understanding the pathophysiology of osteopenia and osteoporosis in Crohn's disease and ulcerative colitis is critical for the correct choice of available treatments or the development of new targeted therapies. In this review, we discuss current concepts explaining the effects of inflammation, inflammatory mediators and their signaling effectors on calcium and phosphate homeostasis, osteoblast and osteoclast function, and the potential limitations of vitamin D used as an immunomodulator and anabolic hormone in IBD.

scholarly journals Does Drinking Coffee and Tea Affect Bone Metabolism in Patients with Inflammatory Bowel Diseases?

Nutrients ◽  
2021 ◽  
Vol 13 (1) ◽  
pp. 216
Author(s):  
Alicja Ewa Ratajczak ◽  
Aleksandra Szymczak-Tomczak ◽  
Agnieszka Zawada ◽  
Anna Maria Rychter ◽  
Agnieszka Dobrowolska ◽  
...  
Keyword(s):  
Bone Metabolism ◽  
Inflammatory Bowel Diseases ◽  
Genetic Factors ◽  
Lower Bone Mineral Density ◽  
Mineral Density ◽  
Bowel Diseases ◽  
Other Substances ◽  
Inflammatory Bowel ◽  
Diet Level ◽  
Affect Bone Metabolism

Patients suffering from Crohn’s disease and ulcerative colitis are at higher risk of osteoporosis due to lower bone mineral density. Risk factors of osteoporosis are divided into unmodifiable, namely, age, gender, genetic factors, as well as modifiable, including diet, level of physical activity, and the use of stimulants. Coffee and tea contain numerous compounds affecting bone metabolism. Certain substances such as antioxidants may protect bones; other substances may increase bone resorption. Nevertheless, the influence of coffee and tea on the development and course of inflammatory bowel diseases is contradictory.

scholarly journals Bone Metabolism in Inflammatory Bowel Diseases 2

2020 ◽  
Vol 66 (7) ◽  
pp. 432-436
Author(s):  
Tomáš Kupka ◽  
Pavel Svoboda ◽  
Martina Bojková ◽  
Martin Blaho ◽  
Adam Vašura ◽  
...  
Keyword(s):  
Bone Metabolism ◽  
Inflammatory Bowel Diseases ◽  
Bowel Diseases ◽  
Inflammatory Bowel

P.14.1 EVALUATION OF BONE METABOLISM DURING ANTI-TNF THERAPY IN INFLAMMATORY BOWEL DISEASES

2016 ◽  
Vol 48 ◽  
pp. e194
Author(s):  
C. Petruzzellis ◽  
L. Sparano ◽  
P. Cesari ◽  
C. Boselli ◽  
F. Pagani
Keyword(s):  
Bone Metabolism ◽  
Inflammatory Bowel Diseases ◽  
Bowel Diseases ◽  
Inflammatory Bowel

scholarly journals Evaluation of interleukin-6 and its soluble receptor components sIL-6R and sgp130 as markers of inflammation in inflammatory bowel diseases

2018 ◽  
Vol 33 (7) ◽  
pp. 927-936 ◽  
Author(s):  
Susanna Nikolaus ◽  
Georg H. Waetzig ◽  
Sven Butzin ◽  
Monika Ziolkiewicz ◽  
Natalie Al-Massad ◽  
...  
Keyword(s):  
Inflammatory Bowel Diseases ◽  
Interleukin 6 ◽  
Soluble Receptor ◽  
Markers Of Inflammation ◽  
Bowel Diseases ◽  
Inflammatory Bowel
Sign in / Sign up

Export Citation Format

Share Document